FLASH radiotherapy: What, how and why?

FLASH radiotherapy: What, how and why?

Ultra-high dose rate (FLASH) radiotherapy is a new way of treating tumours caused by cancer. Higher doses of radiotherapy are associated with trauma to the healthy tissue surrounding the tumour, whereas FLASH radiotherapy demonstrates a sparing effect of the healthy tissues without compromising the anti-tumour action. Dr Kristoffer Petersson at the Oxford Institute for Radiation Oncology, University of Oxford, along […]

Read More…

Overcoming resistance to cancer immunotherapy

Overcoming resistance to cancer immunotherapy

Immunotherapy, which uses the body’s own immune system to fight cancer, is a great step forward in cancer treatment. Unfortunately, however, it is currently ineffective in most patients. This resistance can be caused by a type of cell called a cancer-associated fibroblast, which builds protective defences around tumours. In a recent study, Professor Gareth Thomas and his team at the […]

Read More…

AMP-activated kinase as a therapeutic target in prostate cancer

Prostate cancer is one of the leading causes of mortality among men worldwide.

Pharmacological treatment of prostate cancer has advanced significantly in recent years. However, while the newest therapies are initially effective in reducing tumour size, most patients eventually develop drug resistance and the recurrence of malignant spread. Professor Inés Díaz-Laviada and her team at the Alcala University in Madrid, Spain, have demonstrated that long-term treatments may induce the transformation of cancer cells […]

Read More…

The adaptive cancer cell: How metastases evolve to resist treatment

PACCs make up a rare but stable population in standard cell culture.

Species adapt to survive in a changing environment through the process of evolution. Evolutionary processes can also take place at the cellular level. Dr Sarah Amend of Johns Hopkins University, Baltimore, USA, is investigating poly-aneuploid cancer cells (PACCs). These large, DNA-laden cells, which are more common in metastatic cancer, develop evolvability: the capacity to evolve. Dr Amend believes that targeting […]

Read More…

Artificial intelligence allows quick and easy diagnosis of pancreatic cancer

Artificial intelligence allows quick and easy diagnosis of pancreatic cancer

The pancreas is an important organ that regulates food digestion and blood sugar levels. Cancers commonly arise in the pancreas, leading to death for over 50,000 patients per year in the U.S. alone. This is due to a lack of effective therapies and a low survival rate for this disease since symptoms arise only in the late stages of disease. […]

Read More…

Integrating molecular epidemiology and microbiome science
How cancer patients respond to therapy

Integrating molecular epidemiology and microbiome science How cancer patients respond to therapy

Understanding the variation in responses to cancer therapeutics would create better treatment for many patients and provide an important basis for further research into new or personalised treatments. It is understood there is a connection between patient response to treatment and their microbiome. However, there is currently a lack of consensus on the microbial signatures present in responsive versus unresponsive […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION